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Changes In c-onc Expression during
Embryonal Carcinoma Cell Differentiation
by Thomas Sejersen,* Pei Jin,* Magnus Rahm,* and
Nils R. Ringertz*
Protooncogenes expressed in murine embryonal carcinoma (EC) cells or their differentiated daughter cells
include more orless ubiquitously expressed protooncogenes such as c-myc, c-K-ras, andc-abl, as well as c-onc
genes with a very restricted expression pattern. Examples ofthe latter are N-myc, c-mos, and int-2. These
c-oncgenesaretranscriptionally activeinECcells, aswell as ingermcellsand/orearlyembryonic cells. When
EC cells are inducedtodifferentiate someprotooncogenes oroncogene-relatedproducts undergochanges in
expression. Thus, EC cell differentiation has been associated with increased expression ofc-src, c-fos, int-1,
int-2, and theepidermal growth factor (EGF) receptor, whereas decreased expression has been observed for
c-mos, c-K-ras, c-myc, N-myc, and platelet-derived growth factor. The relationships between these changes
in expression and EC cell differentiation are notunderstood. They may be important forthe differentiation
process orforexpression ofadifferentiatedphenotype. Theymay, however, alsobe secondaryevents with no
functional significance to EC cell differentiation.
Introduction
Protooncogenes (c-onc) are normal cellular genes
homologous to the transforming retroviral oncogenes
(v-onc). c-onc Genes arepresumedtobe ofkeyimportance
inthe control ofcellproliferation and developmental pro-
cesses. This notion first arose from demonstrations that
transforming oncogenes canreducegrowthrequirements
of cells and interfere with various differentiation path-
ways (1). More recentfindings that some protooncogenes
encode growth factors and growth factor receptors pro-
vided evidence that protooncogenes are involved in cel-
lular growth control. Protooncogene products appear to
function asgrowthregulators also as membrane-bound or
intracellular mediators and as nuclear proteins. The im-
portance ofthese genes fordevelopment and differentia-
tion processes is, however, still largely unknown.
Teratocarcinoma cells provide interesting models for
studiesoftherelationshipbetweenprotooncogene expres-
sion, cell proliferation, and differentiation. Teratocarci-
nomas are malignant tumors derived from primordial
germ cells, parthenogenetically activated oocytes, or from
young, ectopic embryos(2). In the mouse, the tumors con-
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sist ofmalignant undifferentiated embryonal carcinoma
(EC) cells, and a variety of differentiated cells. The EC
cells closelyresemble embryoblasts ofthe innercellmass
of the blastocyst. EC stem cells are small, have a high
nucleo-cytoplasmic ratio, and contain few organelles. The
differentiated cell types are derived from the stem cells
(3). Among the cell types commonly found in differen-
tiated teratomas are derivatives ofmore than one germ
layer, e.g., nerve, skin, muscle, andcartilage (Fig. 1). The
multipotency ofEC stemcellshasbeen demonstratedby
showingthat EC cells can differentiate into every tissue
ofperfectly normally developing chimeric mice derived
from implanted blastocysts injected with EC cells (4-6).
AstheEC cellsdifferentiate, theyalsoloose theirtumori-
genicpotential (7). Thepurpose ofthis paperis to review
the present knowledge of how differentiation of em-
bryonal carcinoma cells relates to changes in protoon-
cogene expression.
c-onc Genes in EC Stem Cells
To date, studies ofprotooncogenes interatocarcinomas
atthe DNA, RNA, orproteinlevelhave notrevealed any
consistent feature distinguishing the malignant em-
bryonal carcinoma cells from their normal cellular coun-
terparts. Two cases ofras gene derangements in terato-
carcinoma celllines have beenreported. DuringpassageSEJERSEN ETAL.
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FIGURE 1. Simplified presentation ofthe earliest pathways ofdifferentiation ofthe early embryo inner cell mass (left) and embryonal carcinoma (EC)
stem cells (right).
ofthe humanteratocarcinoma cell line PAl, N-ras has un-
dergone a point mutation at the codon for amino acid
twelve (8). In the other case, a 10- to 20-fold amplification
ofc-K-ras was detected in the genome ofthe murine em-
bryonal carcinoma cell line PCC4(9). This isnot, however,
a general feature of embryonal carcinoma cells, as such
amplification is not found in other embryonal carcinoma
cell lines (10).
c-onc Expression during EC Cell
Differentiation
Oncogenes are commonly classified as belonging to one
offour orfive subgroups, depending onpossible function
and intracellular localization. In the following sections,
differentiation-related changes in c-onc expression willbe
described for each class ofoncogene. The protooncogenes
described are listed in Table 1, summarizing the classifi-
cation system used here.
c-onc Genes Encoding Protein
Kinases
c-src
The expression of c-src, which encodes a plasma and
cytoplasmic membrane-bound tyrosine kinase, is acti-
Table 1. onc-Related genes expressed in embryonal carcinoma cells before or after induced differentiation.
c-onc Cellular location Possible function Expression Reference
Protein kinases
c-src Plasma and cyto- Tyrosine kinase Transcriptional activation in nerve cells (11,15)
plasmic membranes derived from P19 and PCC7
c-abl Plasma and cyto- Tyrosine kinase Several EC cell lines; no association with (22,23)
plasmic membranes differentiation
c-erb-B Plasma and cyto- EGF receptor Differentiated derivatives of several EC cell (26,27)
plasmic membranes Tyrosine kinase lines
c-mos Cytoplasm Serine/threonine 311 EC cells; downregulated in differentiated (36)
kinase 311 cells
Growth factors
c-sis Secreted PDGF B-chain PDGF-like activity secreted by EC stem (40,41)
PDGF A Secreted PDGF A-chain cells
GTPases
c-H-ras Plasma membrane GTP binding and Unaltered expressions in differentiating F9 (46)
hydrolysis cells
c-K-ras Plasma membrane GTP binding and Downregulation in differentiating F9 cells (46)
hydrolysis
Nuclear proteins
c-myc Nucleus ? Posttranscriptional downregulation in (13,46,
differentiating mouse EC cells 56-57,59,69)
N-myc Nucleus Posttranscriptional downregulation in (13,51,59)
differentiating mouse EC cells
c-fos Nucleus ? Induced in differentiating P19 cells (62)
Other c-onc products
int-1 Secreted ? Segment polarity Low expression in PSA-1 embryoid bodies (68)
gene ?
int-2 Secreted ? Growth factor ? Induced in F9 and PSA-1 endoderm (68)
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vated in PCC7 EC cells undergoing neuronal differenti-
ation (11). PCC7 cells differentiate spontaneously into
cholinergic neurons (12), butnerve formation is enhanced
by culturingthe cells inretinoic acid(RA), cAMP, andlow
(2%) serum content. PCC7 cells induced in this way ex-
press 4.0 kb c-src transcripts.
Activation ofc-srcexpression canbe explained by an in-
crease in the transcription rate ofthe c-src gene, which
is transcriptionally silent in PCC7 stem cells(13)(Fig. 2).
It is not yet known ifthe src protein in these cells is of
the modified type expressed at high levels in neural tis-
sue ofthe central nervous system(14). Themodifiedform
ofpp6Osrc was, however, recently found to be induced in
P19 embryonal carcinoma cells treated withretinoic acid
to form neuronlike cells (15).
As a comparison with in vivo embryonic development
ofthe mouse, c-src transcripts first accumulate to detect-
able levels approximately 10 days after fertilization (16).
The biological function ofc-src is not known, but it is in-
terestingto note that expression ofc-src is correlated to
N-myc
TRANSCRIBED
mRNA ABUNDANT
TRANSCRIBED
mRNA SCARCE
c-myc
NOT TRANSCRIBED
NO mRNA
NOT TRANSCRIBED
NO mRNA
c-src
NOT TRANSCRIBED
NO mRNA
TRANSCRIBED
mRNA EXPRESSED
FIGURE 2. Regulation of N-myc. c-myc, and c-src in PCC7 stem cells (left) and in differentiated PCC7 nervelike cells (right). Differentiated PCC7
cells extend neurite outgrowths and accumulate neurofilaments, acetylcholinesterase, and choline acetyltransferase (11,12).
249SEJERSEN ETAL.
terminally differentiated neuronal cells, andnottorapidly
dividing cells. The role ofc-src may thus be to perform a
specialized cellularfunction unrelatedto cellgrowth. This
function may differin different celltypes,justas the v-src
product affects target cells differently. Thus, v-src inhibits
myogenic (17,18), chondrogenic (19), and melanoblastic
(20) differentiation, but induces pheochromocytoma cells
to undergo neuronal differentiation (21).
c-abl
c-abl Encodes a tyrosine kinase closely related to the
product ofc-src. The c-abl gene is expressed both in EC
stem cells and in visceral endoderm, parietal endoderm,
trophoblastic cells, and myogenic cells derived from EC
cells (22). No marked difference in c-abl expression has
been observedbetweenc-abl expression in EC stem cells
and differentiated teratoma-derived cells (23). Similarly,
c-abl expression is relatively constant during mouse
prenatal development (23).
c-erb-B
Epidermal growth factor (EGF) receptors, like other
growth factor receptors, show tyrosine kinase activity
(24). The gene for the EGF receptor is now known to be
identical to c-erb-B(25). Duringretinoic acid-induced en-
dodermal differentiation ofmouse EC cells, the number
ofunoccupied epidermal growth factor (EGF) receptors
increases (26,27)(Fig. 3). Whetherthe apparentincrease
in EGF receptors on differentiating PCC4, PC13, and
OC15S1 EC cells is due to unmasking of receptors oc-
cupied by growth factors produced by EC stem cells or
whetherthe increase represents atrue increaseinthe ac-
tual numberofEGF receptors isnotyetknown. Norhas
itbeenclearlyestablishedifEGFreceptorsareexpressed
bybothparietal andvisceral endoderm. BindingofEGF
to its receptors on differentiated embryonal carcinoma
cells catalyzes phosphorylation oftyrosine residues (28)
and stimulates cell division(26). Inearlymurine develop-
ment, embryonic tissues bind EGF specifically from day
11 ofgestation (29).
Similartothe situation with EGF receptors, PC13 EC
stem cells express few, if any, receptors for insulin,
whereas the differentiated derivative cells express alarge
numberofinsulinreceptors and are stimulated to divide
byinsulin(30). F9 andOIT-6050 EC cellsdo,however, ex-
pressreceptorsforbothinsulinandinsulinlikegrowthfac-
tor II (IGF-II) (31-33). Insulin and IGF-II also promote
the growth ofthese cells (31-34).
c-mos
Expression ofc-mos, encoding acytoplasmically located
serine/threonine kinase, is suppressed in most differen-
tiated tissues andwasfor some timebelieved tobe incom-
patiblewithnormal, untransformedcellgrowth. However,
c-mos is now known to be expressed in mouse testes,
ovaries, andterm embryos(35). mos-Related transcripts
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FIGURE 3. Simplified presentation ofproduction ofgrowth factors and
expressionofgrowthfactorreceptorsbyEC stem cells(left), andEC-
derivedendoderrnal cells(right). Theillustrationisbasedonfindings
in several different cell lines (see text), and is therefore not applica-
ble to any particular EC cell line.
have also been detected inpluripotential murine 311 EC
stem cells(36). Aftera3-daylagperiod, c-mos expression
is strongly inhibited when 311 EC cells are induced by
retinoic acid treatment to undergo differentiation into a
variety ofcelltypes. The sizesofthemajortranscripts in
embryo andinEC 311 cells differ, being 1.3 and2.3 kb in
the embryos and 6.1 and 4.6 kb in EC 311 cells. These
sizes differinturnfromthoseofc-mostranscripts derived
from testes (1.7 kb) or ovaries (1.4 kb). The reason for
these differences is not known.
All ofthese different-sized transcripts are sufficiently
longto coverthe 1 kb openreadingframe ofc-mos. InEC
cell lines other than 311, such as F9, PCC3, and PCC4,
c-mos expression has not been detected (22,23,36). The
role ofc-mos in early embryonal cellgrowth and differen-
tiation is not clear. Aninterestingobservation is that in-
fection with v-mos-carrying retrovirus enhances
anchorage-independent growth of PCC4 EC cells but
doesnotaffecttheabilityofPCC4cellstoundergoepider-
mislike differentiation (37).
c-onc Genes Encoding Growth
Factors
C-SiS and PDGF-A Genes
Platelet-derived growthfactor(PDGF) is a30kDpoly-
peptide consisting oftwo chains, A and B, linked by di-
sulfidebonds. PDGF isapotentmitogenformesenchymal
cells(38). There is approximately40% amino acidhomol-
ogy between the A and B chain. The A chain is encoded
by the PDGF A-chain gene, and the B chain is encoded
byc-sis. AuthenticplateletPDGF mostlikely consists of
A-B heterodimers, but other cells are known to produce
A-A or B-B homodimers. Although mitogenic, A-A
homodimers are considerably lesspotent than authentic
PDGF(39). PDGF-like activityhasbeenfoundinmedium
conditioned by mouse embryonal carcinoma cells (40,41)
(Fig. 3). EC cells appear to express PDGF as A-A
homodimers (Charles Stiles, personal communication).
PDGF B-chain-like RNAis, however, presentbothin EC
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cells and in early mouse embryos (16,22). Differentiation
of F9 and PC-13 EC cells into endodermal cells is
paralleled by a drastic (< 90%) reduction in PDGF pro-
duction. Atthe same time there is a 18- to 85-foldincrease
in PDGF binding activity (41) (Fig. 3). Expression of
PDGF receptors, as well as a mitogenic response to
PDGF, havebeennotedin amesodermal cellline derived
from P19 EC cells (42).
In addition to PDGF-like growth factors, undifferen-
tiated EC cells also produce and secrete transforming
growth factorlike activity (43), basic fibroblastgrowth fac-
tor activity (44), and three other unidentified stem cell
growth factors (45).
c-onc Genes Encoding GTPases
c-ras
p2lras proteins constitute a large family ofmembrane-
bound GTPases. Most studies ofteratoma cells describe
the abundance ofc-K-ras and c-H-ras transcripts. F9 EC
stem cells express both c-K-ras and c-H-ras mRNA (46).
Retinoic acid- and cAMP-induced differentiation of F9
cells into parietal endoderm is accompanied by a moder-
ate decrease in c-K-ras expression, but essentially un-
changedlevels ofc-H-ras. However, F9 cells differentiated
into visceral endoderm by growth as embryoid bodies in
the presence ofretinoic acid do not show altered mRNA
levels ofeither c-K-ras or c-H-ras (23). These results in-
dicate that p2lras proteins are not involved in EC cell
differentiation processes.
A similar conclusion canbe drawn fromtransfection ex-
periments. P19 EC cells transfected with the EJbladder
carcinomacellline oncogene (Ha-msEJ-1) differentiate into
the same spectrum ofcell types(neurons, astrocytes, and
fibroblastlike cells) as the parental P19 cells (47). At the
DNAlevelViletteetal. (10)havefound a 10- to20-fold am-
plification ofc-K-ras inthe mouse EC celllinePCC4, and
Thinsky et al. (8)have reported apoint mutation ofthe N-
ras gene inthe humanteratocarcinoma cell line PAl. As
a comparison with normal mouse embryogenesis, expres-
sion ofH-ras remains fairly constant duringthe prenatal
development (16), whereas c-K-ras is downregulated (48).
c-onc Genes Encoding Nuclear
Proteins
myc Family
The threebest-characterized members ofthe mycfam-
ily ofprotooncogenes are c-myc, N-myc, and L-myc. Ex-
pression ofc-myc is nearly ubiquitous inproliferating tis-
sue, whereas high-level expression of N-myc and L-myc
appears to be very restricted with respect to tissue and
stage ofdevelopment (49). Aninteresting exception to the
nearly ubiquitous expression ofc-myc is found in mouse
testes, where actively dividingpremeiotic germ cells con-
tain extremely low levels of c-myc transcripts (50).
In mouse EC stem cells, both c-myc and N-myc tran-
scripts are expressed at relatively high levels (11,46,51).
The same appearstobethe caseforc-myc and N-myc ex-
pression at the proteinlevel(C. Waters, personal commu-
nication). The EC cell line PCC7 constitutes an exception,
expressing N-myc but not c-myc at the RNA level (11),
aswell as attheproteinlevel(Fig. 4). Thus, c-myc expres-
sion does not appear to be mandatory for rapid prolifer-
ation of EC cells. It can also be speculated that expres-
sion ofa myc-like protein is required for proliferation of
EC cells and that N-myc or some other member of the
growing myc family can substitute for c-myc.
Both N-myc and c-myc expression have been found to
be downregulated in murine EC cells following differen-
tiation into visceral endoderm, parietal endoderm, or
nervelike cells (11,51). Teratoma-derived myoblasts ex-
pressingc-mycbutnot N-myc also downregulate thelevel
ofc-myc transcripts duringterminal differentiation (11).
However, in a subclone of the human pluripotent tera-
tocarcinoma cell line Tera-2, retinoic acidinduced differen-
tiation is not accompanied by decreased c-myc RNA
levels (52). On the contrary, there appears to be a slight
increase in the abundance ofc-myctranscripts. Further-
more, the level ofthep62c-mYc protein appears to increase
with increasing differentiation ofhuman teratomas (53).
The reasonforthe differencein c-mycregulation inTera-2
cells andmurine EC cellsisnotknown,butitmay to some
extent reflect the differences in early embryonic markers
between human and murine teratocarcinoma cells. In
many respects murine EC cells resemble cells ofthe in-
ner cell mass, while human teratocarcinoma stem cell
lines express characteristics ofpreblastocysts, trophecto-
derm, and trophoblastic giant cells (54,55).
Differentiation of F9 EC cells into visceral endoderm
leads to induction of a-fetoprotein expression, reduced
DNA synthesis(80%), and decreasedlevels ofc-myc and
N-myc transcripts (85%) (11) (Fig. 5). The expression of
both myc genes is reduced before transcription of the
gene for the visceral endoderm marker a-fetoprotein is
initiated. The downregulation of c-myc and N-myc
mRNAs do, however, follow different kinetics. The reduc-
tion ofc-myc mRNAprecedes that ofN-mycmRNA(13).
Directingthe differentiation ofF9 EC cells towardparie-
tal endoderm causes a similar reduction in c-myc and
N-myc expression(51). The reduction in c-myc expression
seems to be an early event also in this case (56).
PCC7 cells treated with retinoic acid and dibutyryl-
cAMP(db-cAMP)will differentiate into aggregates ofneu-
rofilamentpositive cellswithmassive neurite outgrowths
(Fig. 2). Very little DNA synthesisis observedin differen-
tiated PCC7 cells. The level ofN-myc mRNA is reduced
by85% in induced PCC7 cells over a6-dayperiod. The de-
crease in N-myc expression israpid duringthefirst 12 hr,
preceding the reduction in DNA synthesis, activation of
the c-src gene, and outgrowth of neurites (11,13). It is,
therefore, temptingto speculate thatthe downregulation
ofN-myc expression is causally related to the differenti-
ation process in retinoic acid treated PCC7 cells.
The complex events constituting differentiation include
both reduced DNA synthesis and marked changes in
phenotype. In orderto examine the relationship between
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FIGURE 4. Expression ofN-nyc (upper right) and c-nyc (ower right) immunoreactivity in PCC7 stem cels. Fixation procedures and exposure times
were the same for both stainings Corresponding phase contrast photographs are shown to the left.
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N-myc
TRANSCRIBED
mRNA ABUNDANT
TRANSCRIBED
mRNA SCARCE
c-myc
TRANSCRIBED
mRNA ABUNDANT
TRANSCRIBED
mRNA SCARCE
c-src
NOT TRANSCRIBED
NO mRNA
NOT TRANSCRIBED
NO mRNA
FIGURE 5. Regulation ofN-myc, c-myc, and c-src in F9 stem cells (left) and in F9-derived endoderm (right). F9-derived visceral endoderm express
a-fetoprotein, have numerous microvilli andvacuoles, andintercellularjunctional complexes (70). The F9endoderm illustrated to theright isprimitive
endoderm.
myc expression and DNA synthesis, F9 and PCC7 EC
stem cells can be partially growth arrested by serum
deprivation. The abundance of both N-myc and c-myc
transcripts is drastically decreased (90%) when F9 cells
are subjected to serum deprivation, a treatment that
causes a marked, but not complete, inhibition of DNA
synthesis (13).
Although both c-myc and N-myc mRNA levels de-
crease radically following serum deprivation ofF9 cells,
the earlykinetics ofthe reappearance ofthesetranscripts
upongrowth stimulation differmarkedlybetweenthetwo
genes Amarkedincrease inc-myc,butnotN-mycexpres-
sion is induced 4 hr after stimulation with either serum
or a combination of insulin and transferrin. Isoleucine
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deprivation, an alternative methodto accomplish partial
growth arrest of EC cells, has been reported by Dean
et al. (57)tobe accompaniedbya similar decline in c-myc
expression. The serum dependence ofN-myc expression
in F9 cells contrasts with the situation in PCC7 cells and
ahumanneuroblastoma cellline. Serum deprivationofthe
latter cell types does not affect the level ofN-myc tran-
scripts (11,58).
The levels of N-myc and c-myc transcripts in the
mRNA population is affected by the rate at which these
genes are transcribed (transcriptional regulation), aswell
as by the stability ofthe transcripts (posttranscriptional
regulation). Invitro nuclearrunofftranscription experi-
ments have been carried out in order to distinguish be-
tween transcriptional and posttranscriptional regulation
in EC cells in response to serum, mitogens, or induction
ofdifferentiation. Theresultsindicatethatbothc-mycand
N-myc are transcribed at a high level in F9 EC cells ir-
respective ofthe state ofdifferentiation (Fig. 5) or pres-
ence ofserum (13,56,57,59). Furthermore, Dony et al. (56)
have demonstrated that the ability of cycloheximide, a
protein synthesis inhibitor, to increase c-myc expression
in F9 cells does not affect c-myc transcription and must,
therefore, affect the mRNA level by stabilizing c-myc
transcripts. It is therefore likely thatthese mycgenes are
regulatedposttranscriptionally, incontrasttothegenefor
a-fetoprotein, which is subject to transcriptional control
(13).
Aquickand efficientposttranscriptional regulation in-
volvingthe stability ofc-myc and N-myc mRNArequires
that the transcripts are short-lived. This has been shown
to be the case forc-myc in anumberofcelltypes(60). The
half-lives of N-myc and c-myc mRNAs in actinomycin
treated F9 stem cells were estimated to be 130 and 40
min, respectively(13). InPCC7 stemcells, theunexpected
absence ofc-myc transcripts appears to be due to lack of
transcription, whereas the reduced levels of N-myc
mRNAfollowing in vitro neuronal differentiation is due
to posttranscriptional events (Fig. 2). This can be con-
trasted withthe c-src gene, which is subject totranscrip-
tional activation.
It is not clearwhether the decreasedexpression ofmyc
genes is in any way causally related to endodermal
differentiation, orifitmerely reflects ageneral inactiva-
tion ofgenes unnecessary forthe specialized visceral en-
doderm. Itis interesting to note, however, thatc-myc ex-
pression undergoes a drastic decrease in mouse
erythroleukemia cells induced to undergo erythroid
differentiation and that expression oftransfected c-myc
blocks this differentiation (61).
c-fos
c-fos, Another protooncogene encoding a nuclear pro-
tein with unknown function, is expressed at high levels
in extra-embryonic membranes, fetal liver, and macro-
phages. Activation ofthe c-fos gene is a veryrapid cellu-
larresponse to serum and anumberofgrowthfactors and
hormones.
STEM CELL
STEM CELL
ENDODERM-LlKE CELL
.
C-FOS
FIGURE 6. F9 stem cells rarely (> 1%) spontaneously give rise to dif-
ferentiated derivatives(upperpathway). Aftertransfection with c-fos,
10-70% ofthecoloniesconsistofdifferentiated cells(lowerpathway)
expressingintermediate filaments TROMA-1 andTROMA-3 as well
as collagen type IV (63,64).
The regulationofc-fos expression in differentiating EC
cellsis not clear. Masonet al. (62)havefoundthatretinoic
acid and cAMP induction ofF9 cells to form parietal en-
dodermis notaccompanied byanylarge increase inc-fos
RNAexpression, althoughparietalendoderm at 13.5 days
ofmurine development express c-fos at very high levels.
Edwards andAdamson(63), ontheotherhand, discovered
alarge increase in c-fos expression as cells ofa subline to
P19were inducedto differentiateinto amixedpopulution
of cell types.
The relationship between c-fos expression and EC cell
differentiation can also be analyzed by studying how
elevated expression oftransfected c-fos gene constructs
affect the ability of EC cells to undergo differentiation.
Ruther et al. (64) found that introduction of metal-
lothionein promoter-driven c-fos genes into F9 cells lead
to the appearance ofc-fos expressingand spontaneously
differentiating clones, usingcellularmorphology andpres-
ence ofthe surface antigens TROMA-1 and TROMA-3 as
differentiation markers (Fig. 6). The phenotype of
differentiated c-fos-transfected F9 cells is, however, not
typical ofeitherprimitive, parietal, orvisceral endoderm
(65). In other EC cell lines, the differentiation-promoting
effect of c-fos is less pronounced (P19) than for F9 cells,
or absent (PC13). Thus, the role of c-fos in EC cell
differentiation remains obscure.
Other c-onc Products in EC Cells
int-i and int-2
int-1 andint-2 differfrom thepreviously described on-
cogenes in thattheywerefirstisolatedfrom DNAaround
proviralintegration sites inmammary carcinomas, rather
than from acutely transforming retroviruses. These se-
quences are not expressed at detectable levels in a vari-
ety ofadultnormalmouse tissues.mnt-1, Recently shown
to be homologous to the Drosophila segment polarity
gene that codes for the wingless phenotype (66), is ex-
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pressed in postmeiotic germ cells and in the developing
central nervous system ofmid-gestation mouse embryos.
Thisgene isnot expressed in F9 or PSA-1 EC stem cells.
Low levels of int-1 RNA appears in embryoid bodies of
PSA-1 cells, but not in F9 cells induced to differentiate
into parietal endoderm. int-i Has no appreciable homol-
ogy with int-2. The lattergene has recently been shown
to be related to the fibroblast growth factorgene family
(67). int-2 Transcripts are found in pern-implantation
mouse embryos and at low levels in F9 and PSA-1 EC
stem cells. In differentiated endodermal derivatives ofF9
and PSA-1, the level ofint-2 expression was found to be
dramatically increased(68). Thephysiological functions of
int-i and int-2 proteins are still poorly understood.
Conclusion
Several protooncogenes are expressed in EC cells or
their differentiated derivatives (Table 1). Althoughpoint
mutations and amplifications of ras genes have been
reported there isno evidence tolinkthemalignantpheno-
type of EC cells to changes in protooncogene structure
or expression. Protooncogenes expressed in germ cells
and/or early embryonic cells are expressed also in EC
cells. Examples ofsuchgenes are N-myc, c-mos, andint-2.
Certain c-oncogenes or oncogene-related products un-
dergo changes in the level ofexpression during induced
differentiation of EC cells. These include c-src, c-mos,
c-erb-B, PDGF, K-ras, c-myc, N-myc, c-fos, int-i, and int-2.
The relationship ofthese changes to EC cell differentia-
tionis notunderstood. Changes inprotooncogene expres-
sion may be important for the differentiation process or
for expression ofthe differentiated phenotype. The pos-
sibility that these changes are secondary events cannot,
however, be excluded. Sofar, the onlyprotooncogene that
has been shown to affect differentiation ofEC cellswhen
expressed atelevatedlevelsis c-fos. Thisresultis difficult
to interpret. We are stillfarawayfromunderstandingthe
role ofprotooncogenes in EC cell differentiation.
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